# Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma

> clinical trial · VERIFIED · 2026-06-04

Status: RECRUITING · Sponsor: Beijing Biotech · Condition: Unresectable Melanoma

- Company: Beijing Biotech
- Sector: cell therapy
- Primary source: https://clinicaltrials.gov/study/NCT07627698

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED.